ID   T47D/TR-2
AC   CVCL_1D37
DR   cancercelllines; CVCL_1D37
DR   CancerTools; 152110
DR   Wikidata; Q54971578
DR   Ximbio; 152110
RX   PubMed=25362855;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1D45 ! T47D/S2
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 05-10-23; Version: 14
//
RX   PubMed=25362855; DOI=10.1038/onc.2014.351;
RA   Thrane S., Pedersen A.M., Thomsen M.B.H., Kirkegaard T.,
RA   Rasmussen B.B., Duun-Henriksen A.K., Laenkholm A.-V., Bak M.,
RA   Lykkesfeldt A.E., Yde C.W.;
RT   "A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as
RT   novel treatment targets in antiestrogen-resistant breast cancer
RT   cells.";
RL   Oncogene 34:4199-4210(2015).
//